Access Consortium 2026 plan for faster medicine access

Five medicines regulators have agreed their 2026 to-do list, centred on getting safe treatments to patients sooner. In a 7 April 2026 statement, the UK’s MHRA said the Access Consortium heads met on 30 March and approved an action plan to speed joint review work across Australia, Canada, Singapore, Switzerland and the UK. The focus is quicker, predictable decisions without lowering standards. (gov.uk)

Quick explainer: the Access Consortium is a partnership between the Therapeutic Goods Administration (Australia), Health Canada, the Health Sciences Authority of Singapore, Swissmedic and the MHRA. It began as ‘ACSS’ in 2007, the UK joined in 2020, and joint work-sharing applications started on 1 January 2021. Together, these regulators serve more than 150 million people. (gov.uk)

Think of work sharing as sensible group work. A company submits largely the same evidence to each country. Instead of five parallel reviews repeating the same tasks, agencies divide parts of the assessment and read each other’s conclusions. Each regulator still makes its own national decision, but duplication falls and scarce expertise stretches further.

Here is what’s new for 2026. Partners will refine the work-sharing process so companies hear back sooner when they send an expression of interest or apply through the Access pathway. The five agencies are also building a shared, secure digital platform so teams can exchange information and track joint projects more easily. (gov.uk)

The agencies also backed fresh development areas. They will explore a reliance approach for clinical trials - in plain terms, using another trusted regulator’s assessment where appropriate - and they will set up a new network linking scientists who test medicine batches for quality before and after launch. (gov.uk)

Because clear messaging matters, the consortium will co-ordinate how it speaks with industry, researchers and the public. Expect a more consistent and open approach across all five regulators, which should help companies plan and help students follow the logic of decisions. (gov.uk)

MHRA Chief Executive Lawrence Tallon summed up the mood: “It’s a privilege to pick up the baton from SwissMedic to lead such productive discussions with our Access partners at this pivotal moment.” He also stressed that faster access for around 150 million patients can go hand-in-hand with meeting national obligations. (gov.uk)

As learners, this is your takeaway. Work sharing is not one mega-approval, and reliance is not blind copying. These are structured ways regulators share evidence and expertise so decisions are quicker and, ideally, clearer to explain. If you’re studying pharmacy, biomedical science or public policy, watch how Access publishes procedures and timelines over 2026.

For patients and prescribers, nothing changes about safety checks or who approves a medicine where you live. Companies, not individuals, use the Access pathway. The promise here is time saved in back-and-forth steps - the consortium will track this by how fast it responds to expressions of interest and applications - while each country keeps full authority over the final call. (gov.uk)

If you want to follow progress, start with the Access Consortium page on GOV.UK for background, working groups and documents, then look for MHRA news posts through the year as the digital platform and trial-reliance ideas take shape. That way we can all check what improves and what still needs work. (gov.uk)